硫酸羟氯喹片用于反复种植失败患者:一项双盲、随机、安慰剂对照试验
本研究计划自2022年12月6日起在5家生殖中心招募686名接受IVF/ICSI的反复种植失败(RIF)患者,随机分为硫酸羟氯喹片组与安慰剂组,从子宫内膜准备开始用药至冻胚移植后14天(未妊娠)或妊娠12周(妊娠)。主要结局为活产率。
要点
- 硫酸羟氯喹作为免疫调节剂在RIF患者中缺乏临床证据,但使用日益增多,亟需随机对照试验阐明其能否改善妊娠结局。
- 计划招募686名志愿者,在5家生殖中心进行双盲、随机、安慰剂对照试验。
- 主要结局为活产率,次要结局包括生化妊娠率、临床妊娠率、胚胎着床率、早期流产率、持续妊娠率等。
核心结论
- 本研究旨在评估羟氯喹(HCQ)能否改善反复种植失败(RIF)患者的妊娠结局,次要目标包括比较干预组与对照组的妊娠并发症。
研究设计与样本
- 双盲、随机、安慰剂对照试验,计划自2022年12月6日起在5家生殖中心招募686名接受IVF/ICSI的志愿者。
- 参与者随机分为两组,从子宫内膜准备开始服用硫酸羟氯喹片或安慰剂,至冻胚移植后14天(未妊娠)或妊娠12周(妊娠)。
主要发现
- 原文未报告结果。
关键数值与推荐
- 主要结局为活产率;次要结局包括生化妊娠率、临床妊娠率、胚胎着床率、早期流产率、持续妊娠率、出生体重、妊娠及围产期并发症、先天畸形及其他不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent implantation failure (RIF) remains clinically unresolved at this stage. Hydroxychloroquine, as an immunomodulator, is still lacking clinical evidence, but it is being used by increasing numbers of reproductive centers and physicians worldwide, so a well-designed randomized controlled trial (RCT) is urgently needed to elucidate whether hydroxychloroquine can improve pregnancy outcomes in patients with RIF. METHODS AND ANALYSIS: In this study, we plan to recruit 686 volunteers who will undergo IVF/ICSI at 5 reproductive centers from 6 December 2022. Participants will be randomized to two parallel groups and treated with hydroxychloroquine sulfate tablets or placebo from the start of endometrial preparation to 14 days after frozen embryo transfer (if not pregnant) or to 12 weeks of pregnancy (if pregnant). The primary outcome is live birth rate, and the secondary outcomes include biochemical pregnancy rate, clinical pregnancy rate, embryo attachment rate, first trimester abortion rate and ongoing pregnancy rate, birth weight, pregnancy and perinatal complications, congenital anomaly, and other adverse events. DISCUSSION: This study aims to evaluate whether hydroxychloroquine (HCQ) improves pregnancy outcomes in patients with recurrent implantation failure (RIF). Secondary objectives include comparative analysis of gestational complications between the intervention and control groups. TRIAL REGISTRATION: ChiCTR2100047584 [Chinese Clinical Trial Registry (ChiCTR): registered on 20 June 2021]. LM2021267 [Ethics Committee of Peking University Third Hospital].
引用
- Han DL, Li L, Shi J, et al. Hydroxychloroquine sulfate tablets for patients with recurrent implantation failure: a double-blind, randomized, placebo-controlled trial. Trials. 2026. PMID: 41612470. doi:10.1186/s13063-026-09470-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。